Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features

Fechine, Carolina Oliveira Costa; Valente, Neusa Yuriko Sakai; Romiti, Ricardo

doi:10.1016/j.abd.2021.08.008

Cited by 22 publications

(41 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several treatment options have been investigated for treating LPP in the literature, but unfortunately, the results are mostly not promising. To date, high potent topical corticosteroids are considered the mainstay of treatment 3,11 . In the past decade, there have been reports of clinical use of pioglitazone in treating LPP with possible therapeutic effectiveness 14–17 .…”

Section: Discussionmentioning

confidence: 99%

“…Clinically, the disease presents as single or multiple scarring alopecic patches, most commonly at the vertex and parietal scalp, with perifollicular scaling, erythema, and a positive hair pull test. In the active phase of the disease, patients may endure significant pruritus, tenderness, or burning in affected lesions 3,4 . The disease primarily affects middle‐aged women 5,6 …”

Section: Introductionmentioning

confidence: 99%

“…While various therapies exist, intralesional and high‐potency topical glucocorticoids and immunosuppressants remain the cornerstone of treatment. Refractory cases may require systemic therapies, hydroxychloroquine, mycophenolate mofetil, cyclosporine, doxycycline, and oral corticosteroids, to name a few 3 …”

Section: Introductionmentioning

confidence: 99%

“…therapies, hydroxychloroquine, mycophenolate mofetil, cyclosporine, doxycycline, and oral corticosteroids, to name a few. 3 Of note, recent research has proposed a down-regulated tissue expression of genes required for lipid metabolism and peroxisome biogenesis in LPP, one of which was the expression of peroxisome proliferator-activated receptor γ (PPAR-γ). Decreased PPAR-γ expression is postulated to result in the accumulation of inflammatory lipids, local inflammation, and subsequent destruction of the pilosebaceous unit typical of LPP.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of oral pioglitazone in the management of lichen planopilaris in comparison with clobetasol: A randomized clinical trial

Lajevardi

Ghiasi

Balighi

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Lichen planopilaris (LPP) is a scarring alopecia for which no treatment with remarkable effect has been identified. Pioglitazone has been reported as a possible therapeutic option. To compare the efficacy and safety of pioglitazone with clobetasol in LPP. This randomized, double-blind, parallel-group was conducted at Razi hospital.Patients were treated either with pioglitazone 15 mg/daily or clobetasol lotion 0.05% once at night for 6 months. Patients were visited every 2 months to assess the lichen planopilaris activity index (LPPAI) and record probable adverse events. Forty patients (mean age: 43.6 years; 62.5% female) were randomized 1:1. The mean of LPPAI at baseline and last session were 4.68 ± 1.97 and 2.59 ± 0.97 in the clobetasol group and 5.01 ± 1.71 and 3.04 ± 1.36 in the pioglitazone group, respectively. Both treatments significantly decreased the LPPAI over the two-month interval visits (p < 0.001). No significant difference in the LPPAI reduction was detected between groups. Regarding the safety profile, three clobetasol-treated patients developed folliculitis, and two in the pioglitazone group developed mild headaches. Pioglitazone effectively controlled the signs and symptoms of the LPP with no serious side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of oral pioglitazone in the management of lichen planopilaris in comparison with clobetasol: A randomized clinical trial

Lajevardi

Ghiasi

Balighi

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Immunosuppressant agents have been abundantly used for treating immunologic-based disorders including LPP. 11,12 However, treating LPP is not an easy task and to date, just a few effective and relatively safe treatment modalities are available for this chronic disorder. MMF has been shown to have a promising effect on LPP with a relatively safe profile in previous studies.…”

Section: Discussionmentioning

confidence: 99%

Clinical efficacy of mychophenolate mofetil in treating lichen planopilaris

Azizpour

Hatami

Lajavardi

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Lichen planopilaris (LPP) is a chronic inflammatory disorder of hair without a proven effective and safe treatment. To objectively assess the clinical efficacy of mycophenolate mofetil (MMF) in patients suffering from LPP, a retrospective cohort study was conducted on 52 patients who treated with MMF (2 g/day) at least for 6 months.LPP activity index (LPPAI) before and after treatment was calculated and compared.Most of the patients were female and belonged to the age group of 50-60 years. All of the disease activity indices were significantly improved after 6 months of therapy (p < 0.001). The majority of patients had LPPAI 4-6 and 0-2, before and after treatment, respectively. After 6 months of treatment, half of patients showed a disease activity decrease (LPPAI reduced >25% compared to the baseline value). Systemic MMF is an effective and relatively safe treatment modality for patients with LPP and could lead to significant reduction in disease activity regarding both subjective and objective indices.

show abstract

Upregulation of caveolae-associated structural proteins in the hair follicle bulge of lichen planopilaris and frontal fibrosing alopecia

Anzai,

Abujamra,

Aoki

et al. 2024

Arch Dermatol Res

View full text Add to dashboard Cite

Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features

Cited by 22 publications

References 52 publications

Efficacy and safety of oral pioglitazone in the management of lichen planopilaris in comparison with clobetasol: A randomized clinical trial

Efficacy and safety of oral pioglitazone in the management of lichen planopilaris in comparison with clobetasol: A randomized clinical trial

Clinical efficacy of mychophenolate mofetil in treating lichen planopilaris

Upregulation of caveolae-associated structural proteins in the hair follicle bulge of lichen planopilaris and frontal fibrosing alopecia

Contact Info

Product

Resources

About